 |
市場調査レポート
商品コード
950713
中国の新型コロナウイルス感染症 (COVID-19) 対策製品市場：2020-2024年China COVID-19 Pandemic Mitigation Products Market 2020-2024: Cumulative 2020-2024 COVID-19 Pandemic Mitigation Market Larger than $188 Billion |
||||||
Homeland Security Research Corporation (HSRC)| 中国の新型コロナウイルス感染症 (COVID-19) 対策製品市場：2020-2024年 |
|
出版日: 2020年07月24日
発行: Homeland Security Research Corporation (HSRC)
ページ情報: 英文 318 Pages; 180 Tables & Figures
納期: 即日から翌営業日
|
当レポートでは、中国の新型コロナウイルス感染症 (COVID-19) 対策製品の市場を包括的に調査し、市場背景、市場成長への各種影響因子の分析、市場規模の推移・予測、製品&サービスタイプ・エンドユーザーなど各種区分別の内訳、事業環境、事業機会、主要企業の動向などをまとめています。
Title:
China COVID-19 Pandemic Mitigation Products
(COVID-19 Drugs Market, COVID-19 Vaccine Market, PPE, Self-collection Swabs, COVID-19 AI, Personal Protection Gear, Teleradiology, Eye Protection, CT, X-Ray, Ultrasound, COVID-19 IT, Telemedicine, PACS, Face Shields, PPE Gowns, Coronavirus Homecare, Mechanical Ventilators, Gloves, E-Health, Robotic PCR Market, Point of Care Antigen Test, PCR Reagents, Face Masks, ICU, Contact Tracing, Sterilization Systems, Point of Care Serologic Test, Polymerase Chain Reaction, Test Kits, Surge Hospitals and More) Market to 2024.
On the backdrop of the need for essential medical products and services, a new market has emerged, the COVID-19 pandemic mitigation products market. The China COVID-19 pandemic mitigation cumulative 2020-2024 market is worth $194-255 billion*.
China cumulative 2020-2024 COVID-19 mitigation products market revenue is forcast to reach: $194 Billion (scenario A); $255 Billion (senario B)
(*) Market size is year and scenario dependent.
To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:
Bottom Line: While other COVID-19 reports are written (at best) by MBAs, this report is published by professionals for experts.
Following a total of 83,462 COVID-19 cases, 4,634 deaths and an extremely long lockdown of 50 million people, China is ahead of the global curve in its recovery from the first wave of the COVID-19 outbreak, with many provinces slowly returning to normal levels of activity. Factories are restarting production and consumers are beginning to spend again. However, the crisis has had a dramatic and prolonged impact on the Chinese economy and healthcare system.
The June outbreak in Beijing has witnessed 260 persons infected with COVID-19 and was a reminder that a every measure should be taken to mitigate future waves.
Take for example democratic Taiwan's success. Taiwan's Center for Disease Control learned from past epidemics and built the National Health Command Center (NHCC) to aid in disaster management for epidemics following the 2004 SARS outbreak. The NHCC built a network of testing labs, a strategic pandemic stockpile and a medical surge capacity. By January, following information about the Chinese coronavirus outbreak, NHCC was engaged in discrete actions to avoid the proliferation of the disease in Taiwan. It conducted screening of flights from Mainland China and the tracking of individual cases. As a result of its early response, Taiwan (population 24 million) had 455 infected and 7 dead - a better outbreak response than in the PRC.
Bottom line: Democratic Taiwan's early control actions and follow-up mitigation measures have received international commendation and endorsement.
Sources: IMF, WHO, OECD, World Population Prospects (2019 Revision)
As for China, only two out of seven elements which contributed to the effective containment of the COVID-19 in China are due to its autocratic regime:
Due to the 2003 SARS outbreak, the Chinese government has been worried about the potential return of the deadly virus. It restructured the country's healthcare system to handle the next outbreak. China extended the laboratory networks to handle the pathogens of infectious diseases; moreover, it founded a new laboratory in Wuhan and another laboratory to study pneumonia with uncertain origins.
It is believed that a quicker publication of the epidemic information was a lesson that China learned from the SARS outbreak as the lack of information release worsened the outbreak.
With the improved public health system, China managed to handle several public health emergencies. In coping with the 2009 H1N1 flu outbreak, China developed and distributed vaccines to 100 million people within months as an active prevention. During the 2013 H7N9 outbreak in East China, the country's health system identified the pathogen five days after the outbreak. Test kits were designed and distributed to all mainland provinces three days after the identification. Within months, effective vaccines were developed. Besides, the Chinese academic community was the first to reveal the virus's transmission methods, molecular mechanisms and effective treatment.
China manufactures the majority of the globe's PPE. In Q-1 2020, as the coronavirus tore through China, forcing it into lockdown, Chinese PPE factories ramped up production. Then China tried to jump-start the economy. With the pandemic spreading throughout the rest of the world, demand for personal protective equipment soared to the point that factory owners in the industry began boasting that they owned money printing machines. As orders of consumer goods shrunk, anxious manufacturers who had the clean rooms and know-how needed to make PPE switched their lines over to make face masks, gloves and PPE gowns.
With demand exploding, full payment up front became the norm. Fraud and counterfeit products proliferated. In April, the PRC government rolled out actions intended to clamp down on counterfeit PPE, and it became even trickier to ship products out of China.
The Chinese government which invested already billions on advanced people surveillance infrastructure based on 230 million video camera backed by face recognition systems extended this infrastructure to mitigate the pandemic. The extension is called the "health code" service.
The "health code" service is run on the ubiquitous smart phone's platforms Alipay and WeChat. It was developed for the government to give users color-coded labels based on their health condition and travel record, and a QR code that can be scanned by government authorities.
As millions of people in China emerge from a long period of lockdown, their freedom of movement is largely dependent on the "health code" apps.
The apps users with a green code are allowed to travel relatively freely. A yellow code indicates that the holder should be in home isolation, and a red one indicates a verified COVID-19 patient who should be in quarantine.
The apps have become an integral part of Chinese authorities' supervision of individuals and their movements in and out of affected areas.
The "health code" service app draws on medical information including: COVID-19 related symptoms (e.g., fever, cough), medical treatment, isolated surveillance, contact information, travel record of the pandemic area, user's travel history including the mode of travel and what seat they sat in, and details on the vehicle and its driver.
This 450 -page market report is the most comprehensive review of the Chinese COVID-19 market available today. The objective of this report is to provide today's strategic decision-makers with an expert 360-degree, time-sensitive, detailed view of this interconnected market.
The ‘China COVID-19 Pandemic Mitigation Products Market - 2020-2024’ report presents a thorough market analysis of 29 products & services, 6 end users, and 4 revenue source markets. Furthermore, the report provides updated extensive data of 37 key vendors.
Moderna, IBM, 3M Company, Philips NV, Johnson & Johnson, Roche, Nvidia Corporation, Thermo Fisher Scientific, Siemens, Toshiba, Google, Samsung Electronics Co, GE Healthcare, Medtronic, MedWhat, MedyMatch, Merck, Metabiota, Micron Technology, Infermedica, Infervision, Inovio Pharmaceuticals, Microsoft Corporation, Mindshare Medical, Morpheo, Pfizer, Philips NV, Maxim Biotech, Honeywell Safety Products, Philips Healthcare, Siemens, Recursion Pharmaceuticals, Fujifilm Holdings Corporation, 3Scan, Abbott , AbCellera, Advenio Technosys, Agfa Healthcare, Agilent Technologies, AiCure, Aindra, Allscripts Healthcare Solutions, Amara Health Analytics, Amazon , analyticsMD, Apixio, Apple, Arterys Inc., Atlas Wearables, Atomwise, Avalon Nutrition VITL, Babylon Health, Bay Labs, Behold.ai, benevolent.ai, BIOBEATS, BlueDot, Bollé Safety, Bullard, Buoy Health, Care Angel Wearables QorQL, Careskore, Clinithink, Cloud Pharmaceuticals, CloudMedx, CureMetrix Mental health Ginger.io, Cyrcadia, Deep 6 AI, Deep Genomics, Dell Technologies Inc., Delta Plus Group, Desktop Genetics Virtual mate Ada Health, DreaMed Diabetes, Dupont, EaglEyeMed, Eli Lilly, Encon Safety Products, Enlitic, EnsoData, Entopsis, Envisagenics Research iCarbonX, ERB Industries Inc., Ergodyne, Essilor of America, Flashback Technologies, Flow Health, Ford, Freenome, Frequency Therapeutics Inc., Gateway Safety Inc., General Motors, General Vision, Gentex Corporation, Gibco, Gilead Sciences, Globavir Biosciences, Healint, Health Fidelity, HealthNextGen, HexArmor, Hindsait, Imagen Technologies, Imagia Cybernetics, Inside DNA, InSilico Medicine, Intel Corporation, Intendu, Invitrogen, Ion Torrent, Ironwear, Jvion, Kapa Biosystems, Keen Eye Technologies, Kimberly-Clark Professional, Lexmark International Inc., LifeGraph, Lucina Health, Lumiata, Lunit, Lytics, Magnea, Maxwell MRI, McKesson Corporation, MCR Safety, Medal, Medalogix, Medasense, MedAware, Niramai Health Analytix, Novarad Corporation, NuMedii, Numerate, Nuritas Pharma Turbine, Oncora Medical, Ovuline, PeerWell, PhysIQ, Precision Health Intelligence, Predible Health, Profility, Proscia, pulseData, Pyramex Safety, Qualaris Healthcare Solutions, Qualcomm Incorporated, Qualcomm Incorporated, Qure.Ai, Radians Inc., Roam Analytics, RxPREDICT, Safety Optical Service Ltd, Sanofi, Saykara, Sellstrom Manufacturing Company (SureWerx), Sense.ly, Sensory Inc., Sigma-Aldrich Corp., Skymind Inc., Vir Biotechnology Inc., VisionAid Inc., WuXi Biologics, Xilinx Inc. and more.
The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen identification, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, ultrasound, electron microscopy, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.
As early as January 20, 2020 we recruited all our analysts to research the COVID-19 pandemic mitigation related products purchases. We interviewed hundreds of experts, participated in more than 95 conferences and webinars, reviewed more than 1,500 publications and interviewed executives of more than 65 pandemic related companies.
比較リスト
